Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 11/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.33 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172355 | 1.00 | PDE2A (0.37) | PDE2AAURKAHCRTR1HCRTR2SPR | |
| SCHEMBL4124966 | 0.84 | AURKA (0.48) | AURKAAURKB | |
| SCHEMBL400511 | 0.82 | AURKA (0.38) | PDE2AAURKASPRAURKBINCENP | |
| SCHEMBL10172360 | 0.82 | AURKA (0.38) | PDE2AAURKASPRAURKBINCENP | |
| SCHEMBL402078 | 0.77 | AURKA (0.46) | AURKAAURKB | |
| SCHEMBL15225692 | 0.77 | AURKA (0.46) | AURKAAURKB | |
| SCHEMBL401815 | 0.75 | AURKA (0.46) | AURKAAURKB | |
| SCHEMBL401220 | 0.75 | P2RX7 (0.36) | AURKASPRAURKBFAAH | |
| SCHEMBL402388 | 0.74 | P2RX7 (0.37) | AURKASPRAURKB | |
| SCHEMBL400939 | 0.74 | P2RX7 (0.37) | AURKASPRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017279-B1 | AMINOPYRIMIDINE DERIVATIVES HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | MSD KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8101621-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2017279-A1 | NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | RB1, AURKA, AURKC | PDE2A 2946/4885AURKA 2/4885HCRTR1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.